![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Leronlimab is a viral-entry inhibitor in HIV/AIDS. This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase III Product Type: Large molecule
Recipient: CytoDyn
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2021